Bitget App
Trade smarter
Buy cryptoMarketsTradeFuturesEarnSquareMore
Kongteng Electronics reported Q2 2026 revenue of $1.58 billion, up 24% year-on-year. Diluted earnings per share were $1.33 (compared to $0.59 in the previous period), an increase of 125% year-on-year. Net profit was $367 million, up 129% year-on-year. Non-GAAP net profit was $582 million, representing a 29% year-on-year increase. Non-GAAP earnings per share were $2.11 (compared to $1.65 in the previous period).

Kongteng Electronics reported Q2 2026 revenue of $1.58 billion, up 24% year-on-year. Diluted earnings per share were $1.33 (compared to $0.59 in the previous period), an increase of 125% year-on-year. Net profit was $367 million, up 129% year-on-year. Non-GAAP net profit was $582 million, representing a 29% year-on-year increase. Non-GAAP earnings per share were $2.11 (compared to $1.65 in the previous period).

智通财经智通财经2026/07/27 23:46
Show original
Kingteng Electronics' revenue for Q2 2026 was $1.58 billion, a year-on-year increase of 24%. Diluted earnings per share were $1.33 (previously $0.59), up 125% year-on-year. Net profit was $367 million, a year-on-year increase of 129%. Non-GAAP net profit was $582 million, up 29% year-on-year. Non-GAAP earnings per share were $2.11 (previously $1.65).
0
0

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.
Trade now!

You may also like

U.S. Stocks Movement | Storage Chip Concept Stocks Rise Across the Board, SNDK (SanDisk) Up 6%

On Monday, storage chip concept stocks generally rose, with SanDisk (SNDK.US) up by 6%.

智通财经2026/08/17 13:51
U.S. Stocks Movement | Storage Chip Concept Stocks Rise Across the Board, SNDK (SanDisk) Up 6%

AstraZeneca (AZN.US) / Daiichi Sankyo ADC first-line lung cancer phase III study succeeds

On August 17, AstraZeneca (AZN.US) and Daiichi Sankyo jointly announced that the Phase III DESTINY-Lung04 study of Enhertu (trastuzumab deruxtecan) as a monotherapy for first-line treatment of non-small cell lung cancer (NSCLC) has achieved highly positive results.

智通财经2026/08/17 12:56
AstraZeneca (AZN.US) / Daiichi Sankyo ADC first-line lung cancer phase III study succeeds